Marketing-authorisation holder
Medimmune Oncology
3 medicines in 2 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
3 medicines in 2 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| NEUTREXIN200mg base/vial | 25mg base/vial · Injectable | Trimetrexate glucuronate | United States | Not marketed | 1993 |
| ETHYOL - PWS IV 500MG/VIAL500 mg / vial · Powder For Solution | Amifostine | Canada | Cancelled | 1996 |
| NEUTREXIN PWS IV 25MG/VIAL25 mg / vial · Powder For Solution | Trimetrexate | Canada | Cancelled | 1994 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 2 | 0 | 2 | CompaniesAll medicines |
| United States | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.